{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T05:47:06Z","timestamp":1778996826163,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013899","name":"M.S.I. Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.cjco.2020.12.026","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T02:21:15Z","timestamp":1611109275000},"page":"703-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antihypertensive Prescribing for Uncomplicated, Incident Hypertension: Opportunities for Cost Savings"],"prefix":"10.1016","volume":"3","author":[{"given":"Amity E.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Ronksley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"McBrien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braden J.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed F.","family":"Beall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2020.12.026_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/HYPERTENSIONAHA.115.05702","article-title":"Healthcare costs attributable to hypertension","volume":"66","author":"Weaver","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2020.12.026_bib3","unstructured":"Patra J, Popova S, Rehm J, et al. Economic cost of chronic disease in Canada. Ontario chronic disease prevention alliance and the Ontario public health association (2007). Available at: https:\/\/www.ocdpa.ca\/sites\/default\/files\/publications\/OCDPA_EconomicCosts.pdf. Accessed April 12, 2021."},{"key":"10.1016\/j.cjco.2020.12.026_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1503\/cmaj.111270","article-title":"The effect of cost on adherence to prescription medications in Canada","volume":"184","author":"Law","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.cjco.2020.12.026_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/M14-2427","article-title":"Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the clinical guidelines committee of the American College of Physicians","volume":"164","author":"Choudhry","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s10620-007-9968-0","article-title":"Medication non-adherence is associated with increased medical health care costs","volume":"53","author":"Kane","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cjco.2020.12.026_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00130832-200406000-00009","article-title":"Medication non-adherence and asthma treatment cost","volume":"4","author":"Bender","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.cjco.2020.12.026_bib8","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1371\/journal.pmed.0040283","article-title":"Physician awareness of drug cost: a systematic review","volume":"4","author":"Allan","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7326\/0003-4819-115-2-116","article-title":"Can physician education lower the cost of prescription drugs?: A prospective, controlled trial","volume":"115","author":"Frazier","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1046\/j.1525-1497.2002.20144.x","article-title":"Modifying provider behavior: a low-tech approach to pharmaceutical ordering","volume":"17","author":"Guterman","year":"2002","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1370\/afm.233","article-title":"Impact of an evidence-based computerized decision support system on primary care prescription costs","volume":"2","author":"McMullin","year":"2004","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1525-1497.2004.30249.x","article-title":"Barriers to patient-physician communication about out-of-pocket costs","volume":"19","author":"Alexander","year":"2004","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib14","first-page":"CD001841","article-title":"First-line drugs for hypertension","volume":"4","author":"Wright","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjco.2020.12.026_bib15","first-page":"CD001841","article-title":"First-line drugs for hypertension","volume":"3","author":"Wright","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjco.2020.12.026_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jch.13055","article-title":"Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: a population-based study","volume":"19","author":"Machado","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2020.12.026_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jch.12622","article-title":"Comparison of the effect of thiazide diuretics and other antihypertensive drugs on central blood pressure: cross-sectional analysis among nondiabetic patients","volume":"17","author":"Moura","year":"2015","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2020.12.026_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1503\/cmaj.121637","article-title":"Addressing cost-related barriers to prescription drug use in Canada","volume":"186","author":"Tang","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.cjco.2020.12.026_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2369-10-30","article-title":"Overview of the Alberta Kidney Disease Network","volume":"10","author":"Hemmelgarn","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cjco.2020.12.026_bib20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.109.139279","article-title":"Validation of a case definition to define hypertension using administrative data","volume":"54","author":"Quan","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2020.12.026_bib21","first-page":"506","article-title":"Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2020.12.026_bib23","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.9778\/cmajo.20190132","article-title":"Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis","volume":"8","author":"Trachtenberg","year":"2020","journal-title":"CMAJ Open"},{"key":"10.1016\/j.cjco.2020.12.026_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","article-title":"Methods for identifying 30 chronic conditions: application to administrative data","volume":"15","author":"Tonelli","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.cjco.2020.12.026_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1715163517701109","article-title":"Cost-effectiveness of pharmacist care for managing hypertension in Canada","volume":"150","author":"Marra","year":"2017","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.cjco.2020.12.026_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/pop.2008.0020","article-title":"Does higher continuity of family physician care reduce hospitalizations in elderly people with diabetes?","volume":"12","author":"Knight","year":"2009","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.cjco.2020.12.026_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinte.167.2.141","article-title":"Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States","volume":"167","author":"Wang","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib28","first-page":"461","article-title":"Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006","volume":"27","author":"Walker","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2020.12.026_bib30","unstructured":"Alberta Health. Alberta Maximum Allowable Cost (MAC) program: angiotensin converting enzyme inhibitors, (2019). Available at: https:\/\/www.ab.bluecross.ca\/pdfs\/MAC-pricing-ACE-inhibitors-details.pdf. Accessed April 12, 2021."},{"issue":"suppl 12","key":"10.1016\/j.cjco.2020.12.026_bib31","first-page":"S13","article-title":"Class-effect with antihypertensive medications: pharmacologic considerations","volume":"11","author":"Sica","year":"2009","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2020.12.026_bib32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","article-title":"Redefining diuretics use in hypertension: why select a thiazide-like diuretic?","volume":"37","author":"Burnier","year":"2019","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjco.2020.12.026_bib33","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1371\/journal.pmed.0030216","article-title":"Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice","volume":"3","author":"Fretheim","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjmed.2011.06.031","article-title":"Risk of thiazide-induced hyponatremia in patients with hypertension","volume":"124","author":"Leung","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2020.12.026_bib36","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/HYPERTENSIONAHA.111.180554","article-title":"Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"59","author":"Alderman","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2020.12.026_bib37","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2020.12.026_bib38","first-page":"547","article-title":"A\u00a0comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers","volume":"5","author":"Sadjadi","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cjco.2020.12.026_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1377\/hlthaff.2018.05372","article-title":"Explaining the slowdown in medical spending growth among the elderly, 1999-2012","volume":"38","author":"Cutler","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.cjco.2020.12.026_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ehjcvp\/pvw042","article-title":"Gender differences in the effects of cardiovascular drugs","volume":"3","author":"Tamargo","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2020.12.026_bib41","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/1060028018779082","article-title":"A\u00a0review of ACE inhibitors and ARBs in black patients with hypertension","volume":"52","author":"Helmer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjco.2020.12.026_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1503\/cmaj.1031010","article-title":"ALLHAT: what has it taught us so far?","volume":"171","author":"Leenen","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.cjco.2020.12.026_bib43","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.12.026_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2020.12.026_bib45","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2020.12.026_bib46","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.12.026_bib47","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.12.026_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.12.026_bib49","doi-asserted-by":"crossref","first-page":"E308","DOI":"10.1503\/cmaj.181041","article-title":"The impact of pharmaceutical rebates on patients\u2019 drug expenditures","volume":"191","author":"Memedovich","year":"2019","journal-title":"CMAJ"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X21000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:03:30Z","timestamp":1762902210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X21000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2589790X21000056"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2020.12.026","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihypertensive Prescribing for Uncomplicated, Incident Hypertension: Opportunities for Cost Savings","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2020.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}